D1025 | noristerat
| Toxicity | Dose | Time | Species | Model | Method | Action | Positive criterion | Reference |
|---|---|---|---|---|---|---|---|---|
| MEMBRANE POTENTIAL | 9.81±1.78 | human | qHTS-HepG2 | MMP assay | decrease | IC50 | 163 | |
| MEMBRANE POTENTIAL | 21.82 | human | HepG2 | MMP assay | decrease | IC50 | 163 | |
| MEMBRANE POTENTIAL | rat | hepatocytes | MMP assay | Negative | IC50 | 163 | ||
| Pictogram | Signal | Statements | Precautionary Statement Codes |
|---|---|---|---|
  |
Danger |
Aggregated GHS information provided by 41 companies from 3 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies. H302 (39.02%): Harmful if swallowed [Warning Acute toxicity, oral] H312 (39.02%): Harmful in contact with skin [Warning Acute toxicity, dermal] H332 (39.02%): Harmful if inhaled [Warning Acute toxicity, inhalation] H351 (97.56%): Suspected of causing cancer [Warning Carcinogenicity] H360 (97.56%): May damage fertility or the unborn child [Danger Reproductive toxicity] H362 (58.54%): May cause harm to breast-fed children [Reproductive toxicity, effects on or via lactation] H413 (58.54%): May cause long lasting harmful effects to aquatic life [Hazardous to the aquatic environment, long-term hazard] Information may vary between notifications depending on impurities, additives, and other factors. The percentage value in parenthesis indicates the notified classification ratio from companies that provide hazard codes. Only hazard codes with percentage values above 10% are shown. |
P201, P202, P260, P261, P263, P264, P270, P271, P273, P280, P281, P301+P312, P302+P352, P304+P312, P304+P340, P308+P313, P312, P322, P330, P363, P405, and P501; (The corresponding statement to each P-code can be found at the GHS Classification page.) |
| (17alpha)-17-((1-Oxoheptyl)oxy)-19-norpregn-4-en-20-yn-3-one | 17-alpha-Ethinyl-19-nortestosterone enanthate | 17-alpha-Ethynyl-17-beta-heptanoyloxy-4-estren-3-one |
| 17-beta-Heptanoyloxy-17-alpha-ethynyl-4-oestren-3-one | 17.alpha.-Ethinyl-19-nortestosterone enanthate | 17.alpha.-Ethynyl-17.beta.-heptanoyloxy-4-estren-3-one |
| 17.alpha.-Ethynyl-19-nortestosterone 17-heptanoate | 17.alpha.-Ethynyl-19-nortestosterone enanthate | 17alpha-Ethinyl-19-nortestosterone enanthate |
| 17alpha-Ethynyl-17beta-heptanoyloxy-4-estren-3-one | 17alpha-Ethynyl-19-nortestosterone 17-heptanoate | 17alpha-Ethynyl-19-nortestosterone enanthate |
| 19-Nor-17-alpha-pregnen-20-ynone, 17-beta-heptanoyloxy- | 19-Nor-17.alpha.-pregn-4-en-20-yn-3-one, heptanate | 19-Nor-17.alpha.-pregn-4-en-20-yn-3-one, heptanoate |
| 19-Nor-17alpha-pregn-4-en-20-yn-3-one, 17-hydroxy-, heptanate | 19-Nor-17alpha-pregn-4-en-20-yn-3-one, 17-hydroxy-, heptanoate (8CI) | 19-Norpregn-4-en-20-yn-3-one, 17-((1-oxoheptyl)oxy)-, (17alpha)- (9CI); |
| 19-Norpregn-4-en-20-yn-3-one, 17-[(1-oxoheptyl)oxy]-, (17a)- | 19-nor-17.alpha.-Pregnen-20-ynone, 17.beta.-heptanoyloxy- | 19-nor-17alpha-Pregnen-20-ynone, 17beta-heptanoyloxy- |
| 3-oxo-19-nor-17alpha-pregn-4-en-20-in-17-yl-heptanot | 3836-23-5 | 836N235 |
| AC-6835 | AKOS015896289 | AS-13385 |
| BCP10922 | BRN 3176529 | C14486 |
| CAS-3836-23-5 | CCRIS 6526 | CHEBI:34894 |
| CHEMBL3187229 | D08285 | DB14678 |
| DSSTox_CID_28590 | DSSTox_GSID_48664 | DSSTox_RID_82861 |
| DTXSID2048664 | EBD15536 | EINECS 223-326-7 |
| HY3S2K0J0F | I041 | LG 202 |
| NCGC00182712-01 | NEE | NORETHINDRONE ENANTHATE |
| NSC 9564 | NSC-22846 | NSC22846 |
| Norethisterone Enantate (Norethindrone Enanthate) | Norethisterone enantate | Norethisterone enanthate |
| Norethisterone oenanthate | Norigest | Noristerat |
| Noristerat (TN) | Norlutin enanthate | Q7050956 |
| SCHEMBL354296 | SH 393 | ST24048794 |
| Sovel | Tox21_113027 | UNII-HY3S2K0J0F |
| WLN: L E5 B666 OV MUTJ E1 FOV6 F1UU1 | ZINC4217172 | [(8R,9S,10R,13S,14S,17R)-17-ethynyl-13-methyl-3-oxo-1,2,6,7,8,9,10,11,12,14,15,16-dodecahydrocyclopenta[a]phenanthren-17-yl] heptanoate |
| norethindrone heptanoate | norethisterone enantate; | s6589 |